Jang Jun-Woo, Lim Dong-Woo, Chang Ji-Ung, Kim Jai-Eun
Department of Pathology, College of Korean Medicine, Dongguk University, Goyang 10326, Republic of Korea.
Evid Based Complement Alternat Med. 2018 Aug 19;2018:5614091. doi: 10.1155/2018/5614091. eCollection 2018.
Gambihwan is a herbal prescription used in Korean medicine to treat obesity. The authors evaluated the effects and mechanisms of two types of Gambihwan (GBH1 and 2) administered to high-fat diet- (HFD-) induced obese mice. Four-week-old C57BL/6 mice were fed a HFD for 8 weeks with or without GBH1 or 2 (100-200 mg/kg/day by oral gavage). All mice were subjected to glucose tolerance testing after the 8-week treatment period and then euthanized. Serum insulin, lipids, and inflammatory cytokine levels were analyzed using commercial kits. Hepatic enzyme levels and lipid profiles were also investigated. Liver section slides were stained with Oil Red O (ORO) or hematoxylin and eosin (H&E) to assess lipid accumulation. GBH1 and 2 both significantly decreased body, liver, or adipose tissue weights in HFD-fed mice and significantly improved glucose tolerance (p<0.05 in all groups). Cholesterol levels in both sera and liver homogenates were significantly decreased by GBH1 and 2 (p<0.05 in all groups). In addition, serum inflammatory cytokines (p<0.05 in 200 mg/kg/day groups) and hepatic enzyme levels were significantly diminished by GBH administration at 200mg/kg/day (p<0.05 in all groups). Furthermore, histologic analyses of liver sections revealed GBH suppressed lipid accumulation. Both GBH types suppressed HFD-induced increases in body weight and obesity-related markers in HFD-fed mice despite the difference in constituents between GBH1 and 2. It is strongly assumed that the combination of and exerted the antiobesity effect. The results obtained show that the antiobesity effects of GBH warrant further investigation.
甘比焕是一种用于韩医学治疗肥胖症的草药方剂。作者评估了给高脂饮食（HFD）诱导的肥胖小鼠施用两种类型的甘比焕（GBH1和GBH2）的效果和机制。将四周龄的C57BL/6小鼠用或不用GBH1或GBH2（通过口服灌胃给予100 - 200毫克/千克/天）喂食高脂饮食8周。在8周治疗期后对所有小鼠进行葡萄糖耐量测试，然后实施安乐死。使用商用试剂盒分析血清胰岛素、脂质和炎性细胞因子水平。还研究了肝酶水平和脂质谱。用油红O（ORO）或苏木精和伊红（H&E）对肝脏切片进行染色以评估脂质积累。GBH1和GBH2均显著降低了高脂饮食喂养小鼠的体重、肝脏或脂肪组织重量，并显著改善了葡萄糖耐量（所有组p<0.05）。GBH1和GBH2均显著降低了血清和肝脏匀浆中的胆固醇水平（所有组p<0.05）。此外，GBH以200毫克/千克/天给药显著降低了血清炎性细胞因子（200毫克/千克/天组p<0.05）和肝酶水平（所有组p<0.05）。此外，肝脏切片的组织学分析显示GBH抑制了脂质积累。尽管GBH1和GBH2的成分存在差异，但两种类型的GBH均抑制了高脂饮食喂养小鼠中高脂饮食诱导的体重增加和肥胖相关标志物。强烈推测 和 的组合发挥了抗肥胖作用。所获得的结果表明GBH的抗肥胖作用值得进一步研究。
